Lipum AB is a biopharmaceutical company dedicated to eliminating or alleviating painful symptoms for millions of patients suffering from chronic inflammatory diseases. Their mission is to develop groundbreaking anti-inflammatory drugs that improve the quality of life for individuals affected by conditions like rheumatoid arthritis (RA), Crohn's disease, and ulcerative colitis. Their flagship medication, SOL-116, is a therapeutic antibody that offers a unique mechanism of action for treating chronic inflammatory diseases.

Lipum's story began 45 years ago with a discovery by researchers at Umeå University, focusing on the study of infant nutrition and the fat-digesting enzyme protein known as bile salt-stimulated lipase (BSSL). Lipum is currently conducting clinical trials for SOL-116, and their dedication to innovative treatments is evident in their commitment to helping those affected by chronic inflammation